Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
03/2010
03/02/2010US7671033 Amphiphilic dendritic dipeptides and their self-assembly into helical pores
03/02/2010US7671032 19-(7-Methoxy-2-phenyl-quinolin-4-yloxy)-2, 16-dioxo-3,15,17-triaza-tricyclo[15.3.0.0*4,6*]icos-7-ene-4,14-dicarboxylic acid 4-ethyl ester 14-methyl ester, for example; inhibits the NS3 protease of flavivirus such as hepatitis C virus (HCV)
03/02/2010US7671031 delivering an amphetamine by administering to said subject in need L-lysine-d-amphetamine or a salt thereof; providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity
03/02/2010US7671030 Administering L-lysine-d-amphetamine or salts
03/02/2010US7671029 Peptide is chemically linked to the carrier moiety through a non-therapeutic linker species; to enhance the absorption and bioavailability of an active peptide drug substance
03/02/2010US7671028 Peptides that antagonize FPR class receptor mediated signaling
03/02/2010US7671027 use of agonist of hypothalamic hormone, i.e. GnRH, for preparation to support luteal phase during infertility treatment of female mammals; pharmaceutical agent supports luteal phase after spontaneous ovulation or after stimulation of follicular growth triggering final follicular maturation and ovulation
03/02/2010US7671026 administering to an interstitial cystitis-afflicted subject a pharmaceutically effective amount of a composition comprising an oligopeptide comprising the disclosed amino acid sequence
03/02/2010US7671025 Neurotensin receptor agonists and opioid receptor agonists
03/02/2010US7671024 Antilipemic agents; anticholesterol agents; antidiabetic agents; hypotensive agents; administering polypeptide; useful for treating obesity-related diseases and disorders
03/02/2010US7671023 administration of an amylin or an amylin agonist to a subject in order to treat psychiatric diseases and disorders, and conditions associated with psychiatric diseases and disorders
03/02/2010US7671022 administering molecules that block endogenous costimulatory (B7) interactions with cytotoxic t lymphocytes(CTLA4) and/or CD28 antigens
03/02/2010US7671021 Peptides that home to tumor lymphatic vasculature and methods of using same
03/02/2010US7671020 Methods of increasing cartilage deposition using FGF homologs
03/02/2010US7671019 Administering enzyme inhibitors; wrinkling and aging resistance; prevents formation Advanced Glycation End Products (AGEs)
03/02/2010US7671018 Applying at the repair site a therapeutically effective amount of a proteoglycan that comprises the amino acid sequence of the core protein of domain I of a mammalian perlecan to which at least one glycosaminoglycan is attached
03/02/2010US7671017 Use of a combination of cyclosporine and pegylated interferon for treating hepatitis C (HCV)
03/02/2010US7671014 delivering carrier matrix to target site within patient by wetting components with fluid to create viscous aggregate comprising BMP-2 and bulking material selected from collagen-ceramic composites, allograft and bio-compatible ceramics or minerals that provide bone ingrowth scaffold, injecting into site
03/02/2010US7671013 method for accelerating the dissolution of a blood clot through the administration of at least one coagulation protein, with or without being in complex with a serpin, comprising a basic C-terminal amino acid, wherein the coagulation protein may be a derivative of Factor X or Factor V
03/02/2010US7671012 Formulations and methods for delivery of growth factor analogs
03/02/2010US7671011 peptide comprises at least two positively charged amino acid residues; the peptide after conjugation to the fatty acid possessing antibacterial, antifungal, and/or anticancer activity higher than prior to conjugation; suitable for treatment of infections caused by pathogenic organisms such as bacteria
03/02/2010US7671010 method of delivering agent to prostate cancer tissue comprising obtaining peptide that selectively binds to prostate cancer tissue, where peptide is less than 100 amino acids in length and includes prostate cancer targeting motif having disclosed amino acid sequence; peptide is attached to target agent
03/02/2010US7671009 Wound healing agents; hydration; wrinkle resistance; aging resistance; radiation resistance; forming collagen, , fibronectin
03/02/2010US7670849 Method for diagnosing insulin resistance from nasal secretions
03/02/2010US7670838 Calcium channel modulators; inhibiting neurogenesis; N-methyl-D-asparate (NMDA) receptors
03/02/2010US7670836 Antimicrobial peptide isolated from Penaeus monodon
03/02/2010US7670835 diagnosis of and vaccination against Streptococcal infections ; detection of virulence markers of Streptococci
03/02/2010US7670817 Dynamin mediated diseases and associated methods and products
03/02/2010US7670805 for determining bioactive intact PTH levels in serum, plasma, and/or cell culture media; have a novel recognition for amino acid residues extending beyond the first N-terminal PTH residue; have binding affinity and specificity for PTH that have mitigated cross-reactivity to large non (1-84) PTH fragments
03/02/2010US7670802 CXC-chemokine antagonists isolated from Rhipicephalus sanguineus
03/02/2010US7670778 Using malignant brain tumor (MBT) repeat protein (LIN-61) as tool in identifying modulators for prevention and treatment of cell proliferative disorders
03/02/2010US7670773 detecting Rett syndrome, a neuropsychiatric disorder
03/02/2010US7670767 Genetic alterations associated with cancer
03/02/2010US7670623 Hemostatic composition
03/02/2010US7670620 Topical composition for the treatment of psoriasis and related skin disorders
03/02/2010US7670618 Pharmaceutical compositions
03/02/2010US7670611 Cancer immunotherapy with semi-allogeneic cells
03/02/2010US7670608 Selection of patients with increased responsiveness to botulinum toxin
03/02/2010US7670605 Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
03/02/2010US7670603 Using toll-like receptor polypeptides to generate atibodies for use in treatment and prevention of septic shock, inflammation and viral infection
03/02/2010US7670602 Concatameric immunoadhesion molecule
03/02/2010US7670601 Using uterine tumor specific marker as diagnostic tool in detection of urogenital specific cell proliferative disorders
03/02/2010US7670600 increased in vivo half-lives due to the presence of an immunoglobulin G (IgG) constant domain; pharmacokinetics; diagnosis or immunotherapy; antibody conjugates; palivizumab
03/02/2010US7670597 Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases
03/02/2010US7670595 Fc-interferon-beta fusion proteins
03/02/2010US7670312 Sensor system including a port body
03/02/2010CA2390659C Ny-eso-1 peptide derivatives, and uses thereof
03/02/2010CA2190359C Nucleic acids of rochalimaea henselae and rochalimaea quintana and methods and compositions for diagnosing rochalimaea henselae and rochalimaea quintana infection
02/2010
02/28/2010CA2676955A1 Method for reducing postprandial blood glucose levels with a whey protein/fiber composition
02/28/2010CA2676518A1 Whey protein pre-load
02/25/2010WO2010022262A2 Methods for treating type i diabetes with leptin and leptin agonists
02/25/2010WO2010022260A2 Novel toxin-antitoxin system
02/25/2010WO2010022217A1 Combinations comprising bicyclic s1p lyase inhibitors
02/25/2010WO2010022213A2 Compositions and methods for preserving pancreatic islet mass
02/25/2010WO2010022198A2 T cell receptors and related materials and methods of use
02/25/2010WO2010022176A1 Methods of treatment for skeletal conditons
02/25/2010WO2010022171A1 Peptidic pth receptor agonists
02/25/2010WO2010022149A1 Complement inhibitors for treatment of injury form intracerebral hemorrhage
02/25/2010WO2010022089A2 Derivatives of apf and methods of use
02/25/2010WO2010022017A2 Method and composition for enhancing hematopoietic stem cell mobilization
02/25/2010WO2010022016A1 Method of treating peyronie's disease
02/25/2010WO2010021928A1 Organoarsenic compounds and methods for the treatment of cancer
02/25/2010WO2010021879A2 Use of ultrarapid acting insulin
02/25/2010WO2010021579A1 Anti-infective compounds and uses thereof
02/25/2010WO2010021570A1 Method for immobilising biologically active substances on polymer carriers (variants) and conjugates produced by said method
02/25/2010WO2010021424A1 Novel use of bacteriocin derived from enterococcus faecalis sl-5
02/25/2010WO2010021412A1 Therapeutic material for cerebral infarction, and method for regeneration of brain tissue
02/25/2010WO2010021112A1 Hig2 and urlc10 epitope peptide and vaccines containing the same
02/25/2010WO2010020822A1 Therapy for apolipoprotein-induced hypertriglyceridemia
02/25/2010WO2010020811A1 Non-cytotoxic fusion proteins comprising egf muteins
02/25/2010WO2010020690A1 Recombinantly produced human factor viii and ix
02/25/2010WO2010020677A2 Protein c variants
02/25/2010WO2010020676A1 The use of topoisomerase type i inhibitors to treat viral infections
02/25/2010WO2010020618A1 Susceptibility to hsp90-inhibitors
02/25/2010WO2010020610A1 Compounds for the treatment of peripheral neuropathies
02/25/2010WO2010020609A1 Amino alcohol derivatives for the treatment of demyelinating peripheral neuropathies
02/25/2010WO2010020254A1 Multilayered blood product
02/25/2010WO2010020004A1 Compositions and methods for inhibition of adipogenesis and the treatment of obesity
02/25/2010WO2009155585A9 Dna-directed customization of analgesic compounds as a therapeutic modality
02/25/2010WO2009149179A3 Enhanced antiviral therapy methods and devices
02/25/2010WO2009148566A3 Development of a c-reactive protein mutant with improved therapeutic benefit in immune thrombocytopenia and lupus nephritis
02/25/2010WO2009146886A3 Antibacterial peptides
02/25/2010WO2009143493A3 MODULATORS OF TNFα-DEPENDENT SIGNALING PATHWAYS AND USES THEREOF
02/25/2010WO2009143309A3 Female reproductive tract and anal prophylaxes
02/25/2010WO2009137795A3 Methods for treating endoplasmic reticulum (er) stress disorders
02/25/2010WO2009137632A3 Hiv immunogen and method of making and using same
02/25/2010WO2009129250A3 Meal-time insulin analogues of enhanced stability
02/25/2010WO2009129205A3 Sparc anti-inflammatory activity and uses thereof
02/25/2010WO2009126308A3 Compositions and methods for vaccine and virus production
02/25/2010WO2009114702A3 Recombinant production of authentic human proteins using human cell expression systems
02/25/2010WO2009111169A3 Compositions comprising pkc-delta modulators and methods for ocular neuroprotection
02/25/2010WO2009109927A3 Glp-1 receptor agonists and related active pharmaceutical ingredients for treatment of cancer
02/25/2010WO2009063069A3 Protein purification and endotoxin removal
02/25/2010WO2008132732A3 Methods and compositions for rectal administration of proteins
02/25/2010WO2008132731A3 Methods and compositions for rectal administration of insulin
02/25/2010WO2008131052A9 Novel peptide amphiphiles having improved solubility and methods of using same
02/25/2010WO2005081873A9 Il-13 mutein proteins, antibodies, compositions, methods and uses
02/25/2010US20100049847 System and Method for Monitoring and Analyzing Internet Traffic
02/25/2010US20100048878 Human gene
02/25/2010US20100048868 Polypeptides Having Binding Affinity for Her2
1 ... 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 ... 3163